Pharmaron Beijing Co., Ltd. (Pharmaron) announced that an employee representatives’ meeting held on 5 June 2026 elected Chief Financial Officer and Board Secretary Mr. Li Shing Chung Gilbert as the employee representative director for the company’s fourth board session.

Mr. Li’s appointment, made in accordance with the PRC Company Law and Pharmaron’s articles of association, does not require separate shareholder approval. His term will begin upon the establishment of the fourth board on 12 June 2026—immediately after the 2025 Annual General Meeting—and will run until the end of that board’s tenure.

Remuneration for Mr. Li’s directorship will follow the company’s existing policies; no additional fees will be paid for the new role. After this election, directors who also hold senior-management positions or serve as employee representatives remain below one-half of the total board size, meeting regulatory and internal governance requirements.

Profile of Mr. Li Shing Chung Gilbert • Age: 47 • Current roles: Chief Financial Officer (since 2015), Board Secretary (since 2016) • Responsibilities: Oversees finance, investment, financing, and M&A activities; serves as supervisor or director of multiple subsidiaries • Career background: Joined Pharmaron in 2008 as Financial Controller; previously Assistant Manager at KPMG (2000–2003) • Education & credentials: BBA, Hong Kong University of Science and Technology; MBA, China Europe International Business School; member of HKICPA and AICPA; Chartered Financial Analyst • Shareholding: Indirectly holds approximately 8.29 million A shares through a minority interest in Pharmaron Holdings Limited; the company confirms he does not control that entity • No disclosed relationships with other directors, senior management, or substantial shareholders, and no directorships in other listed companies over the past three years.

Pharmaron’s board expressed its welcome for Mr. Li’s continued service as the company prepares for the next governance cycle.